Importantly, in this publication, we refuted the initial hypothesis about the potential use of selective 5-HT6R antagonists in the treatment of high-grade gliomas, as no correlation between high affinity and antiproliferative activity was observed. The gene discussed is HTR6; the disease is central nervous system cancer.